Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S145-50. doi: 10.1016/j.ijrobp.2009.08.076.
Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.
生物标志物对于预测或监测放射治疗的正常组织毒性具有重要意义。分子放射生物学的进展为寻找具有足够敏感性和特异性的正常组织生物标志物提供了新的线索，使其成为临床上有用的方法。本文综述了生物标志物作为预测标志物、反应标志物或放射副作用替代终点的研究实例。单核苷酸多态性在候选基因和全基因组关联研究的背景下进行了简要讨论。强调了在正常组织生物标志物研究中调整放射剂量分布的重要性。最后，确定并讨论了该领域的研究重点。
